COGT - Cogent Biosciences, Inc.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 10.47

Open

Bid

$ 10.48 x 100

Ask

$ 10.49 x 200

Day's Range

-- - --

52 Week Range

$ 3.67 - $ 12.65

Volume

982,327

Average Volume

Market Cap

1.15B

Beta (5Y Monthly)

$ 1.24

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-26-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-14-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	03-15-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-16-2021	06-30-2021	10-Q
14	05-12-2021	03-31-2021	10-Q
15	03-16-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-11-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	03-26-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-12-2019	06-30-2019	10-Q
22	05-13-2019	03-31-2019	10-Q
23	03-28-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q
25	08-13-2018	06-30-2018	10-Q
26	05-14-2018	03-31-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Baird Maintains Neutral on Cogent Bioscien...
09/05/2024 11:31:03

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $8 to $10.

HC Wainwright & Co. Maintains Buy on Cogen...
09/03/2024 15:06:29

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and lowers the price targ...

Cogent Biosciences Says Patient Enrollment...
09/03/2024 12:10:09

Based on strong global patient interest, a total of 413 patients were enrolled in the study. In addition, Cogent recently compl...

JP Morgan Maintains Overweight on Cogent B...
08/07/2024 18:07:15

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and lowers the price target from ...

5Needham Reiterates Buy on Cogent Bioscien...
08/07/2024 11:13:46

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

Cogent Biosciences Q2 EPS $(0.59) Misses $...
08/06/2024 12:15:31

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of ...

Needham Reiterates Buy on Cogent Bioscienc...
06/27/2024 15:44:26

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

Cogent Biosciences Announces FDA Meeting A...
06/27/2024 12:05:07

Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defin...

HC Wainwright & Co. Reiterates Buy on Coge...
06/17/2024 10:36:19

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price ...

Needham Reiterates Buy on Cogent Bioscienc...
06/17/2024 09:44:54

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

Cogent Biosciences Reveals Additional Data...
06/14/2024 11:40:27

Wedbush Reiterates Neutral on Cogent Biosc...
05/24/2024 13:54:33

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Neutral and maintains $10 price target.

Cogent Biosciences Reports Updated Lead-In...
05/23/2024 21:09:35

PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024

HC Wainwright & Co. Reiterates Buy on Coge...
05/13/2024 10:34:31

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price ...

Needham Reiterates Buy on Cogent Bioscienc...
05/08/2024 09:56:16

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

Cogent Biosciences Q1 EPS $(0.62) Misses $...
05/07/2024 12:03:35

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of ...

marinus-pharmaceuticals-neumora-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Marinus Pharmaceuticals, Neumora Therapeut...
04/15/2024 12:19:30

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Cogent Biosciences Reported Preclinical Da...
04/09/2024 13:13:44

JP Morgan Maintains Overweight on Cogent B...
02/27/2024 18:00:20

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...

Citigroup Maintains Buy on Cogent Bioscien...
02/26/2024 16:45:43

Citigroup analyst David Lebowitz maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $11 ...